These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 19360426)
21. β-Amyloid, cholinergic transmission, and cerebrovascular system -- a developmental study in a mouse model of Alzheimer's disease. Kuznetsova E; Schliebs R Curr Pharm Des; 2013; 19(38):6749-65. PubMed ID: 23530514 [TBL] [Abstract][Full Text] [Related]
22. Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Wegiel J; Kuchna I; Nowicki K; Frackowiak J; Mazur-Kolecka B; Imaki H; Wegiel J; Mehta PD; Silverman WP; Reisberg B; Deleon M; Wisniewski T; Pirttilla T; Frey H; Lehtimäki T; Kivimäki T; Visser FE; Kamphorst W; Potempska A; Bolton D; Currie JR; Miller DL Acta Neuropathol; 2007 Apr; 113(4):389-402. PubMed ID: 17237937 [TBL] [Abstract][Full Text] [Related]
23. Generation and Partial Characterization of Rabbit Monoclonal Antibody to Pyroglutamate Amyloid-β3-42 (pE3-Aβ). Mehta PD; Patrick BA; Barshatzky M; Mehta SP; Frackowiak J; Mazur-Kolecka B; Wegiel J; Wisniewski T; Miller DL J Alzheimers Dis; 2018; 62(4):1635-1649. PubMed ID: 29504532 [TBL] [Abstract][Full Text] [Related]
24. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice. Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786 [TBL] [Abstract][Full Text] [Related]
25. Diversity in Aβ deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis. Xu G; Fromholt SE; Chakrabarty P; Zhu F; Liu X; Pace MC; Koh J; Golde TE; Levites Y; Lewis J; Borchelt DR Acta Neuropathol Commun; 2020 Apr; 8(1):43. PubMed ID: 32252825 [TBL] [Abstract][Full Text] [Related]
26. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease. Sabbagh MN; Fleisher A; Chen K; Rogers J; Berk C; Reiman E; Pontecorvo M; Mintun M; Skovronsky D; Jacobson SA; Sue LI; Liebsack C; Charney AS; Cole L; Belden C; Beach TG Arch Neurol; 2011 Nov; 68(11):1461-6. PubMed ID: 22084131 [TBL] [Abstract][Full Text] [Related]
27. Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down Syndrome. Head E; Azizeh BY; Lott IT; Tenner AJ; Cotman CW; Cribbs DH Neurobiol Dis; 2001 Apr; 8(2):252-65. PubMed ID: 11300721 [TBL] [Abstract][Full Text] [Related]
28. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. Chung E; Ji Y; Sun Y; Kascsak RJ; Kascsak RB; Mehta PD; Strittmatter SM; Wisniewski T BMC Neurosci; 2010 Oct; 11():130. PubMed ID: 20946660 [TBL] [Abstract][Full Text] [Related]
29. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. Kawarabayashi T; Shoji M; Younkin LH; Wen-Lang L; Dickson DW; Murakami T; Matsubara E; Abe K; Ashe KH; Younkin SG J Neurosci; 2004 Apr; 24(15):3801-9. PubMed ID: 15084661 [TBL] [Abstract][Full Text] [Related]
30. Neuronal localization of C1q in preclinical Alzheimer's disease. Fonseca MI; Kawas CH; Troncoso JC; Tenner AJ Neurobiol Dis; 2004 Feb; 15(1):40-6. PubMed ID: 14751769 [TBL] [Abstract][Full Text] [Related]
31. The presence of isoaspartic acid in beta-amyloid plaques indicates plaque age. Fonseca MI; Head E; Velazquez P; Cotman CW; Tenner AJ Exp Neurol; 1999 Jun; 157(2):277-88. PubMed ID: 10364440 [TBL] [Abstract][Full Text] [Related]
32. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S Elife; 2020 Jun; 9():. PubMed ID: 32510331 [TBL] [Abstract][Full Text] [Related]
33. Early-onset formation of parenchymal plaque amyloid abrogates cerebral microvascular amyloid accumulation in transgenic mice. Xu F; Kotarba AE; Ou-Yang MH; Fu Z; Davis J; Smith SO; Van Nostrand WE J Biol Chem; 2014 Jun; 289(25):17895-908. PubMed ID: 24828504 [TBL] [Abstract][Full Text] [Related]
34. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Cenini G; Dowling AL; Beckett TL; Barone E; Mancuso C; Murphy MP; Levine H; Lott IT; Schmitt FA; Butterfield DA; Head E Biochim Biophys Acta; 2012 Feb; 1822(2):130-8. PubMed ID: 22009041 [TBL] [Abstract][Full Text] [Related]
35. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates. Venkataramani V; Wirths O; Budka H; Härtig W; Kovacs GG; Bayer TA J Alzheimers Dis; 2012; 29(2):361-71. PubMed ID: 22232007 [TBL] [Abstract][Full Text] [Related]
37. Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. Schmidt ML; Robinson KA; Lee VM; Trojanowski JQ Am J Pathol; 1995 Aug; 147(2):503-15. PubMed ID: 7639340 [TBL] [Abstract][Full Text] [Related]
38. Fibrillar Amyloid-β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3×Tg-AD Transgenic Mouse. Ontiveros-Torres MÁ; Labra-Barrios ML; Díaz-Cintra S; Aguilar-Vázquez AR; Moreno-Campuzano S; Flores-Rodríguez P; Luna-Herrera C; Mena R; Perry G; Florán-Garduño B; Luna-Muñoz J; Luna-Arias JP J Alzheimers Dis; 2016 Mar; 52(1):243-69. PubMed ID: 27031470 [TBL] [Abstract][Full Text] [Related]